Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Cash from Financing Activities (2021 - 2024)

Opus Genetics (IRD) has disclosed Cash from Financing Activities for 7 consecutive years, with $3.6 million as the latest value for Q4 2023.

  • On a quarterly basis, Cash from Financing Activities rose 30125.0% to $3.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $9.0 million, a 137.16% increase, with the full-year FY2024 number at $4.2 million, down 53.38% from a year prior.
  • Cash from Financing Activities was $3.6 million for Q4 2023 at Opus Genetics, down from $5.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $18.0 million in Q2 2021 to a low of -$12000.0 in Q4 2022.
  • A 3-year average of $3.6 million and a median of $1.6 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 91.16% in 2022, then surged 30125.0% in 2023.
  • Opus Genetics' Cash from Financing Activities stood at $1.6 million in 2021, then crashed by 100.75% to -$12000.0 in 2022, then soared by 30125.0% to $3.6 million in 2023.
  • Per Business Quant, the three most recent readings for IRD's Cash from Financing Activities are $3.6 million (Q4 2023), $5.4 million (Q3 2023), and -$12000.0 (Q4 2022).